CorDynamics Publishes Pulmonary Arterial Hypertension Study

Chicago, IL (November 2011) In collaboration with Corridor Pharmaceuticals, CorDynamics demonstrated the novel serotonin receptor antagonist C-122 prevents monocrotaline induced pulmonary arterial hypertension in rats in a paper published in the European Journal of Pharmacology. Current therapies for pulmonary artery hypertension (PAH) improve longevity and performance of daily activities in the lives of PAH patients, but do not notably affect the disease processes that lead to morbidity and mortality. Since serotonin has a definitive role in the development of PAH, the authors hypothesized that interfering with serotonin function may reduce the vascular remodeling and hemodynamic changes that occur in this preclinical model.

“We are excited to present these compelling pulmonary hypertension results in collaboration with Corridor,” says Dr. Michael Gralinski, CorDynamics CEO. “As the industry continues to evolve, we believe that working in a collaborative environment enables better research that will ultimately provide more treatment options for patients in the future.”

CorDynamics, Inc. is a comprehensive contract research organization and consulting group focused on examining the cardiovascular effects of emerging drug candidates. The company provides support with discovery and preclinical safety pharmacology studies along with lead optimization screening and consulting for more than 200 biopharmaceutical clients worldwide.

To learn more about CorDynamics, please visit our website or contact Dr. Gralinski at mrg@cordynamics.com. .

Contact:
Michael R. Gralinski, Ph.D., CorDynamics CEO